Patent Assignment
Reel/Frame 070786/0163
First Supplement to Patent Security Agreement
Recorded: 2025-04-09
Pages: 10
Assignor
KERYX BIOPHARMACEUTICALS, INC.
Executed: 2025-03-26
Assignee
KREOS CAPITAL VII (UK) LIMITED
12 THROGMORTON AVENUE, C/O BLACKROCK INVESTMENT MANAGEMENT (UK) LIMITED - PRIVATE DEBT-EMEA VENTURE & GROWTH LENDING GROUP, LONDON, EC2N 2DL, UNITED KINGDOM
Covered Properties
(3)
Pediatric Formulations of Ferric Citrate
Application:
18/517,274 →
Publication:
US 2024/0100011
Ferric Citrate Dosage Forms
Application:
18/743,646 →
Publication:
US 2025/0144064
Use of Ferric Citrate in the Treatment of and the Reduction of Mortality and Morbidity Related to Adverse Cardiac Events in Chronic Kidney Disease Patients
Application:
19/006,830 →
Publication:
US 2025/0360167
Related Assignments
(4)
Other recorded transfers of the patents in this record — the chain of ownership.
Security Interest
Jan 29, 2024
From: AKEBIA THERAPEUTICS, INC.; KERYX BIOPHARMACEUTICALS, INC.
To: KREOS CAPITAL VII (UK) LIMITED
Reel/Frame 066377/0654 →
Assignment of Assignor's Interest
Feb 8, 2024
From: KNEZIC, DRAGUTIN; PATEL, ANIRUDDH; SEYEDI, FARZANEH; ARULMOZHI, ANANDHAVALAVAN
To: KERYX BIOPHARMACEUTICALS, INC.
Reel/Frame 066413/0777 →
Assignment of Assignor's Interest
Oct 10, 2024
From: LE, HENRY TRONG
To: KERYX BIOPHARMACEUTICALS, INC.
Reel/Frame 068866/0697 →
Assignment of Assignor's Interest
Jan 7, 2025
From: PORADOSU, ENRIQUE; OLIVIERO, JAMES F., III; BENTSUR, RON
To: KERYX BIOPHARMACEUTICALS, INC.
Reel/Frame 069763/0530 →